Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL

A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It remains unclear if the long-term response is associated with the characteristics of CAR T cells in infusion products, hinderi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Zhiliang, Woodhouse, Steven, Zhao, Ziran, Arya, Rahul, Govek, Kiya, Kim, Dongjoo, Lundh, Stefan, Baysoy, Alev, Sun, Hongxing, Deng, Yanxiang, Xiao, Yang, Barrett, David M., Myers, Regina M., Grupp, Stephan A., June, Carl H., Fan, Rong, Camara, Pablo G., Melenhorst, J. Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177075/
https://www.ncbi.nlm.nih.gov/pubmed/35675405
http://dx.doi.org/10.1126/sciadv.abj2820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177075/
https://www.ncbi.nlm.nih.gov/pubmed/35675405
http://dx.doi.org/10.1126/sciadv.abj2820

Ejemplares similares